JPMorgan has upgraded Illumina's stock to Overweight from Neutral and increased its December 2026 price target to $185 from $125, reflecting what the bank describes as growing confidence that the DNA sequencing company can sustain robust growth in the face of intensifying competition.
The bank said recent surveys and industry channel checks reduce prior concerns that customers might migrate away from Illumina's sequencing platforms. Those checks indicated that Illumina's largest clinical customers remain strongly committed to its ecosystem, JPMorgan said, pointing to substantial switching costs and broad adoption of Illumina's NovaSeq X platform as reinforcing factors.
JPMorgan highlighted a survey of 62 research and clinical customers which, the bank reported, showed expectations for accelerating spending on sequencing instruments and consumables through 2027 and 2028. Respondents to the survey also projected gains in Illumina's share of next-generation sequencing activity. The bank noted that clinical customers in particular expect rising testing volumes and increased equipment purchases.
On demand drivers, JPMorgan pointed to structural growth in precision medicine as a key support for sequencing consumption. The bank listed therapy selection, minimal residual disease - MRD - monitoring, and multi-cancer early detection - MCED - testing as areas likely to sustain demand. JPMorgan also cited rising sequencing intensity as laboratories expand into whole-genome sequencing, RNA sequencing and broader multiomics workflows.
While acknowledging competitive pressure from Roche's Axelios 1 platform, the bank identified specific factors that could slow customer uptake of that rival system. JPMorgan said concerns over workflow complexity, risks associated with reusable flow-cell contamination, and higher DNA input requirements for the competitor platform may hamper adoption and thereby support Illumina's position in the clinical market.
On the financial outlook, JPMorgan expects Illumina's clinical consumables business to generate low- to mid-teens growth in the coming years, which the bank believes will help the company achieve high-single-digit organic revenue growth from 2027 onward. The firm projects revenue rising to $4.58 billion in 2026 from $4.34 billion in 2025, with adjusted earnings per share increasing to $5.23 from $4.84. JPMorgan further expects Illumina to sustain a mid- to high-teens earnings growth profile through the end of the decade.
Summary of the bank's stance:
- Upgrade in recommendation to Overweight, with a December 2026 price target raised to $185 from $125.
- Survey and channel checks of large clinical customers indicate strong attachment to Illumina's ecosystem and anticipated spending growth on instruments and consumables.
- Structural drivers in precision medicine and rising sequencing intensity seen as supportive of sustained demand for sequencing solutions and consumables.
The upgrade reflects JPMorgan's read of customer commitment, expected consumables growth and secular drivers in genomic testing that together underpin Illumina's revenue and earnings outlook, according to the bank's analysis.